Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business UpdatePRNewsWire • 08/04/22
Theravance Biopharma to Report Second Quarter 2022 Financial Results on August 4, 2022PRNewsWire • 07/28/22
Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/26/22
Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023PRNewsWire • 07/26/22
Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total ValuePRNewsWire • 07/13/22
Is the Options Market Predicting a Spike in Theravance (TBPH) Stock?Zacks Investment Research • 06/06/22
Theravance Biopharma's (TBPH) CEO Rick Winningham on Q1 2022 Results -Earnings Call TranscriptSeeking Alpha • 05/07/22
Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/06/22
Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business UpdatePRNewsWire • 05/05/22
Theravance Biopharma to Report First Quarter 2022 Financial Results on May 5, 2022PRNewsWire • 05/02/22
Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/26/22
Theravance Biopharma's Ampreloxetine Shows Benefit In Atrophy Patients, But Not In Parkinson'sBenzinga • 04/05/22
Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)PRNewsWire • 04/04/22
Theravance Biopharma's (TBPH) CEO Rick Winningham on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/24/22
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdatePRNewsWire • 02/23/22